Clinical significance of Bcl-6 expression in young DLBCL patients with Myc+ or Bcl-2+Myc+ / 肿瘤
Tumor
;
(12): 858-865, 2018.
Article
in Chinese
| WPRIM
| ID: wpr-848346
ABSTRACT
Objective:
To investigate the expression of Bcl-6 in newly diagnosed and young patients with diffuse large B cell lymphoma (DLBCL), and to further explore its clinical significance in young DLBCL patients with Myc positive expression (Myc+) or Bcl-2 and Myc positive expressions (Bcl-2+Myc+).Methods:
Immunohistochemical (IHC) staining was used to detect the expressions of Bcl-6, Myc and Bcl-2 in 116 newly diagnosed and young patients with DLBCL, and the complete clinical and pathological data were collected. The relationship between the expression levels of Bcl-6 protein and the prognosis of young DLBCL patients with Myc+ and Bcl-2+Myc+ was retrospectively analyzed.Results:
There was no significantly correlation between the expression of Bcl-6 alone and the prognosis of young DLBCL patients (P > 0.05). However, for the DLBCL patients with Myc+, the prognosis in Bcl-6 negative (Bcl-6–) group was worse than that in Bcl-6 positive (Bcl-6+) group (P < 0.05). Furthermore, the multivariate COX regression analysis showed that Bcl-6–Myc+ expression was a significant independent factor of adverse prognosis except for the international prognostic index (IPI) (P < 0.05). Meanwhile, the prognosis of DLBLC patients with Bcl-6–Bcl-2+Myc+ was significantly worse than that of the patients with Bcl-6+Bcl-2+Myc+ (P < 0.05).Conclusion:
Bcl-6 negative expression can increase the risk of poor prognosis in young DLBCL patients with Myc+ or Bcl-2+Myc+.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Prognostic study
Language:
Chinese
Journal:
Tumor
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS